Latest Feature

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Subscribe to the MassDevice
Enter your email:

Need Medtech news in a minute? We Deliver!

MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Philips wins FDA nod for 3D TAVI planning software

August 21, 2014 by Brad Perriello

Philips Healthcare wins 510(k) clearance from the FDA for its 3D planning software for transcatheter aortic valve implants.

Philips wins FDA nod for 3D TAVI planning software

Will Medtronic abandon inversion in Covidien deal? | Medtech Wall Street news for the week of August 18, 2014

August 21, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; ElectroCore seeks commercial partners for non-invasive headache tech; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Activist investor battles on over ConMed as shareholders vote approaches; Medtronic's Q1 earnings beat The Street on modest sales bump

Will Medtronic follow Walgreen and abandon inversion in Covidien deal?

August 15, 2014 by Brad Perriello

Direct Flow wins CE Marks for TAVI device

August 21, 2014 by Brad Perriello

Direct Flow Medical wins CE Mark approval in the European Union for the smallest size of its replacement heart valve and another EU nod for implanting the device without contrast media.

Direct Flow wins CE Marks for TAVI device

Direct Flow Medical said today that it won CE Mark approval in the European Union for an additional size of its replacement heart valve, plus an EU OK for the use of the devices without contrast media.

Covidien opens Brazilian training center | On Call

August 21, 2014 by Arezu Sarvestani

Covidien launches 1st-of-its-kind Center of Innovation in CEO Jose Almeida's home country of Brazil. On Call

MASSDEVICE ON CALL — Medtech titan Covidien (NYSE:COV) cut the ribbon on a new training center in Sao Paulo, Brazil, the home country of president & CEO Jose Almeida. +3 | The top 3 medtech stories for August 20, 2014

August 20, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.


FDA delays UDI rule for contacts, intraocular lenses

August 20, 2014 by Arezu Sarvestani

The FDA gives Class III contact and intraocular lens manufacturers a 1-year extension to comply with the Unique Device Identifier program.

FDA delays UDI rule for high-risk contacts, intraocular lenses

Makers of contact lenses and intraocular lenses are getting a 1-year reprieve after the FDA agreed to shift their due date for complying with Unique Device Identifier rules.

Manufacturers successfully lobbied for a delay after demonstrating that requirements for lenses would create a massive burden for both device makers and regulators.

Covidien's atherectomy study finally hits JACC

August 20, 2014 by Arezu Sarvestani

Final results from Covidien's DEFINITIVE LE study, originally closed in 2012, finally appear in the Journal of American College of Cardiology, Cardiovascular Interventions.

Covidien's atherectomy study hits JAMA

It may have taken 2 years but final results from Covidien's (NYSE:COV) DEFINITIVE LE study finally appeared in the Journal of the American College of Cardiology's Cardiovascular Interventions issue.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp